Xiaoqing Yao

Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies

Xiaoguang Chen, Yuke Liu, Yan Li, 2021, Frontiers in Pharmacology.

Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis.

Shao Li, Xin Wang, Weihua Wang, 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey

Dechang Chen, Yi Yang, H. Qiu, 2019, Critical care medicine.

YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

T. Du, Yunchen Wang, Xiaoguang Chen, 2022, Acta pharmaceutica Sinica. B.

Epidemiological Study of Sepsis in China: Protocol of a Cross-sectional Survey

Jian-feng Xie, Cong-shan Yang, H. Qiu, 2016, Chinese medical journal.

Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.

B. Zang, Yunbo Sun, P. Hu, 2023, Journal of critical care.

Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug

L. Luo, Xiaoguang Chen, Yuke Liu, 2021, Pharmaceutics.